1Gema F, et al. To adipocyte: a model for integration of endocrine and metabolic signaling in energy metabolism regulation[J]. Am J physical Endocrinal Metab 2001 ;280:E827- E847.
2Hrnicar J, Garbor D, HrnciarovaM, et al, Relation between cytokine(TNF-alpha, IL- 6 and 1)and homocysteine in android obesity and the phenomenon of insulin resistance syndromes[J]. Vnitr Lek 1999;45:11- 16.
3Esposito K, et al. Inflammation cytokine concentrations are acutely increased by hyperglycemia in human: role of oxidative stress[J]. Circulation 2002 ; 106 : 2067 - 2072.
4Hilgendorff A, Muth H, Parviz B, Staubitz A, et al. Statins differ in their ability to block NF - kappaB activation in human blood monocytes. Int J Clin Pharmacol Ther 2003 ; 41(9) : 397 - 401.
5Rezaie - Majd A, Prager GW, Bucek RA, Schernthaner GH, et al. Simvastatin reduces the expression of adhesion molecules in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Yasc Biol 2003;23(3):397-403.
6Neuhaus(), Strasser - Fuchs S, Fazekas F. et al. Statins as immunomodulators[J]. Neurology 2002 ;59(8):990 - 997.
1Mykkanen L, Haffner S M, Ronnemaa T, et al. Is there a sex difference in the association of plasma insulin level and insulin sensitivity with serum lipids and lipoproteins? Metabolism, 1994,43:523～528.
3Lakka H M, Lakka T A, Tuomilehto J, et al. Hyperinsulinemia and the risk of cardiovascular death and acute coronary heart disease risk factor study. Arch Intern Med, 2000,160:1160～1168.
4Robins S J, Rubins H B, Faas F H, et al. Insulin resistance and cardiovascular events with low HDL cholesterol: the veterans affairs HDL intervention trial(VA-HIT). Diabetes Care, 2003,26:1513～1517.
5Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4s). Lancet, 1994,344:1383～1389.
6The BIP Study Group. Secondary prevention by raising HDL-cholesterol and reducing triglycerides in patients with coronary artery disease: the bezafibrate infarction prevention (BIP) study. Circulation, 2000,102:21～27.
7Shepard J, Blauw G J, Murphy M B, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomized controlled trial. Lancet, 2002,360:1623～1630.
8ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care. The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT). JAMA, 2002,288:2998～3007.
9Sever P S, Dahlof B, Poulter N R, et al. Prevention of coronary and stroke events with atorvastation in hypertensive patients who have average or lower-than-average cholesterol concentrations in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomized controlled trial.Lancet, 2003,361:1149～1158.
